An underperforming India unit and US price pressures business took their toll on Zydus Cadila during Q3FY22, but the company’s outlook could become more favorable heading into H2, owing to potential ZyCov-D COVID-19 vaccine exports and biosimilar launches.
Pressure Mounts On Zydus Cadila In Q3 As Vaccine Launch Looms
Indian Firm May See Fortunes Change As ZyCov-D And Biosimilars Reach Market
Zydus Cadila found itself under pressure during Q3 following a lack of demand for COVID-19 therapeutics in India and reduced mesalamine sales in the US – but, heading into H2, exports of its novel COVID-19 vaccine ZyCov-D, as well as a number of biosimilar launches, could see its luck begin to turn.
More from Earnings
• By
Teva is charting a new course under its ‘Pivot to Growth’ strategy, providing a memory aid for investors to better understand the firm’s financials going into 2025.
• By
With sales and profits shooting up in 2024, Alvotech has revealed plans to rapidly accelerate development to add between four and six programs to its pipeline of biosimilars every year, while at the same time unveiling details of several new brands that it will be seeking to challenge. The firm has also set out longer-term financial targets that anticipate more than trebling its revenues in the next three years.
• By
The Chinese player reported its second profitable year in a row, with growth in sales reported across its marketed portfolio and further milestones in the near future.
• By
After announcing updates in its ongoing legal battle and a leadership shakeup earlier this fiscal year, Hyloris closed 2024 with a slight rise in revenue and a shrinking of its reported net loss.
More from Business
Gedeon Richter has filed its Mochida-partnered tocilizumab biosimilar rival to RoActemra with the European Medicines Agency. But with several biosimilars already having won approval, the market could be competitive.
• By
Accord received positive opinions for its Prolia and Xgeva biosimilars at the latest meeting of the EMA’s CHMP. Meanwhile, Celltrion picked up a nod for another Stelara biosimilar, while Rechon Life Science withdrew an application for human insulin.
• By
With Celltrion having just received approval for its US Actemra (tocilizumab) biosimilar and having just launched its ustekinumab rival to Stelara – and with the introduction of the Korean developer’s denosumab rivals to Prolia and Xgeva just around the corner – 2025 is set to be a busy year, Celltrion USA chief commercial officer Thomas Nusbickel tells Generics Bulletin.